The CEO of BioArctic talks Leqembi and what's next in Alzheimer's, Parkinson's, ALS, and more

blonca9
Sep 21, 2024
1 min read

Gunilla Osswald talks about the global approvals Leqembi has received, she makes the case for a European approval, and talks about what BioArctic has in R&D, including a "BrainTransporter" technology that helps get antibodies into the brain more efficiently.

Recent Posts

See All

Anglo Nordic Life Science Conference: Denmark based Synklino is developing a fusion protein that targets US28 for CMV infections from transplants

On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress

BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round

The CEO of BioArctic talks Leqembi and what's next in Alzheimer's, Parkinson's, ALS, and more

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight